Sivik Global Healthcare LLC Buys Shares of 2,500 argenex SE $ARGX

Key Points

• Sivik Global Healthcare LLC has purchased 2,500 shares of argenex SE (NASDAQ:ARGX) for approximately $1,378,000 in the second quarter.
• Analysts have a consensus "Buy" rating for argenex, with price targets ranging from $766.00 to $1,070.00, indicating significant optimism regarding the stock's future performance.
• In the last quarter, argenex SE reported an earnings per share of $3.74, exceeding estimates by $0.90, along with revenue of $866.79 million, surpassing expectations of $776.82 million.

Sivik Global Healthcare LLC bought a new stake in argenex SE (NASDAQ:ARGX - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,500 shares of the company's stock, valued at approximately $1,378,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. lifted its stake in argenex by 56.4% in the first quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after acquiring an additional 22 shares during the last quarter. WPG Advisers LLC acquired a new stake in shares of argenex in the first quarter worth $37,000. Golden State Wealth Management LLC acquired a new stake in shares of argenex in the first quarter worth $44,000. Brooklyn Investment Group lifted its stake in shares of argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company's stock worth $44,000 after buying an additional 38 shares during the last quarter. Finally, Banque Transatlantique SA acquired a new stake in shares of argenex in the first quarter worth $62,000. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

ARGX has been the subject of a number of analyst reports. Morgan Stanley boosted their price objective on shares of argenex from $766.00 to $1,040.00 and gave the stock an "overweight" rating in a research note on Wednesday, October 1st. Royal Bank Of Canada initiated coverage on shares of argenex in a research note on Monday, August 25th. They issued an "outperform" rating and a $850.00 price objective for the company. Guggenheim restated a "buy" rating and issued a $1,070.00 price objective on shares of argenex in a research note on Thursday, September 18th. Wedbush restated an "outperform" rating and issued a $800.00 price objective on shares of argenex in a research note on Monday, August 25th. Finally, Deutsche Bank Aktiengesellschaft cut shares of argenex from a "buy" rating to a "hold" rating in a research note on Thursday, September 11th. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $813.32.

argenex Price Performance

NASDAQ:ARGX opened at $796.92 on Friday. The stock has a market cap of $48.77 billion, a P/E ratio of 40.87, a PEG ratio of 0.86 and a beta of 0.46. argenex SE has a one year low of $510.05 and a one year high of $808.43. The company has a fifty day moving average price of $719.96 and a 200 day moving average price of $627.76.

argenex (NASDAQ:ARGX - Get Free Report) last released its earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million during the quarter, compared to analysts' expectations of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. As a group, equities research analysts anticipate that argenex SE will post 3.13 EPS for the current year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.